1. Subjects who have previously been infected with SARS-CoV2 (symptomatic or asymptomatic) and recovered. <br/ >2. Subjects who are known to be HIV, HBV, HCV positive. <br/ >3. Subjects who have clinically abnormal renal or hepatic function values that are 3x times normal upper limit or in the opinion of the Investigator would impact the objectives of the study. <br/ >4. Subjects with complete cancer remission less than 3 years prior to the date of screening. <br/ >5. Subjects who have undergone major surgical procedure 4 weeks prior to randomisation. <br/ >6. Subjects who are on anti-depressants, anti-psychotics. <br/ >7. Subjects with known history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases, except those that are considered etiology of said indication. <br/ >8. Females who are pregnant or nursing or planning to become pregnant during the study period. <br/ >

1. Subjects who have previously been infected with SARS-CoV2 (symptomatic or asymptomatic) and recovered. <br/ >2. Subjects who are known to be HIV, HBV, HCV positive. <br/ >3. Subjects who have clinically abnormal renal or hepatic function values that are 3x times normal upper limit or in the opinion of the Investigator would impact the objectives of the study. <br/ >4. Subjects with complete cancer remission less than 3 years prior to the date of screening. <br/ >5. Subjects who have undergone major surgical procedure 4 weeks prior to randomisation. <br/ >6. Subjects who are on anti-depressants, anti-psychotics. <br/ >7. Subjects with known history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases, except those that are considered etiology of said indication. <br/ >8. Females who are pregnant or nursing or planning to become pregnant during the study period. <br/ >

N/A

N/A

1. Subjects who have previously been infected with SARS-CoV2 (symptomatic or asymptomatic) and recovered. <br/ >2. Subjects who are known to be HIV, HBV, HCV positive. <br/ >3. Subjects who have clinically abnormal renal or hepatic function values that are 3x times normal upper limit or in the opinion of the Investigator would impact the objectives of the study. <br/ >4. Subjects with complete cancer remission less than 3 years prior to the date of screening. <br/ >5. Subjects who have undergone major surgical procedure 4 weeks prior to randomisation. <br/ >6. Subjects who are on anti-depressants, anti-psychotics. <br/ >7. Subjects with known history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases, except those that are considered etiology of said indication. <br/ >8. Females who are pregnant or nursing or planning to become pregnant during the study period. <br/ >

1. Subjects who have previously been infected with SARS-CoV2 (symptomatic or asymptomatic) and recovered. <br/ >2. Subjects who are known to be HIV, HBV, HCV positive. <br/ >3. Subjects who have clinically abnormal renal or hepatic function values that are 3x times normal upper limit or in the opinion of the Investigator would impact the objectives of the study. <br/ >4. Subjects with complete cancer remission less than 3 years prior to the date of screening. <br/ >5. Subjects who have undergone major surgical procedure 4 weeks prior to randomisation. <br/ >6. Subjects who are on anti-depressants, anti-psychotics. <br/ >7. Subjects with known history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases, except those that are considered etiology of said indication. <br/ >8. Females who are pregnant or nursing or planning to become pregnant during the study period. <br/ >